
Ji-Youn Han

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/15871/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 2027-2039.	13.9	691
2	CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). Journal of Clinical Oncology, 2018, 36, 2702-2709.	0.8	359
3	Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 2021, 39, 3391-3402.	0.8	320
4	Comprehensive Analysis of UGT1A Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non–Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin. Journal of Clinical Oncology, 2006, 24, 2237-2244.	0.8	293
5	Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer, 2007, 110, 138-147.	2.0	188
6	Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. Journal of Thoracic Oncology, 2021, 16, 2091-2108.	0.5	156
7	A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research, 2011, 17, 1553-1560.	3.2	117
8	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study. Lancet Oncology, The, 2019, 20, 1681-1690.	5.1	92
9	Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer, 2009, 63, 115-120.	0.9	91
10	Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer, 2008, 59, 69-75.	0.9	90
11	JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2019, 37, 9009-9009.	0.8	74
12	Association of <i>p53</i> codon 72 polymorphism and <i>MDM2</i> SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer, 2008, 113, 799-807.	2.0	67
13	Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. Journal of Thoracic Oncology, 2018, 13, 636-648.	0.5	67
14	Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 475-483.	1.1	62
15	Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. Oncotarget, 2016, 7, 69450-69465.	0.8	60
16	The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. Lung Cancer, 2006, 54, 227-234.	0.9	55
17	A nomogram to predict brain metastasis as the first relapse in curatively resected non-small cell lung cancer patients. Lung Cancer, 2015, 88, 201-207.	0.9	55
18	Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2020, 38, 9512-9512.	0.8	54

JI-YOUN HAN

#	Article	IF	CITATIONS
19	A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer, 2013, 79, 137-142.	0.9	46
20	Phase II Study of Irinotecan Plus Cisplatin Induction Followed by Concurrent Twice-Daily Thoracic Irradiation With Etoposide Plus Cisplatin Chemotherapy for Limited-Disease Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 3488-3494.	0.8	45
21	Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. Lung Cancer, 2014, 85, 161-167.	0.9	43
22	Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. Cancer Research and Treatment, 2017, 49, 1001-1011.	1.3	43
23	A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2022, 17, 558-567.	0.5	43
24	A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensiveâ€disease small cell lung cancer. Cancer, 2011, 117, 2178-2185.	2.0	40
25	PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer. BMC Cancer, 2016, 16, 627.	1.1	40
26	The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy. Radiation Oncology, 2014, 9, 283.	1.2	32
27	Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of Clinical Oncology, 2021, 39, 2791-2802.	0.8	32
28	A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma. Cancer, 2003, 98, 1918-1924.	2.0	30
29	A phase II study of nintedanib in patients with relapsed small cell lung cancer. Lung Cancer, 2016, 96, 108-112.	0.9	30
30	Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as firstâ€line chemotherapy with secondâ€line crossover in patients with advanced nonsmall cell lung cancer. Cancer, 2008, 113, 388-395.	2.0	27
31	Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. Lung Cancer, 2011, 74, 293-299.	0.9	24
32	Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1–Mediated Lung Cancer. Molecular Cancer Therapeutics, 2018, 17, 2024-2033.	1.9	24
33	Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer, 2006, 106, 873-880.	2.0	23
34	Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer. Lung Cancer, 2021, 151, 8-15.	0.9	23
35	DNA repair gene polymorphisms and benefit from gefitinib in neverâ€smokers with lung adenocarcinoma. Cancer, 2011, 117, 3201-3208.	2.0	22
36	EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion. Lung Cancer, 2018, 124, 71-75.	0.9	22

JI-YOUN HAN

#	Article	IF	CITATIONS
37	A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. Clinical Cancer Research, 2003, 9, 5909-14.	3.2	19
38	Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy. Pharmacogenomics Journal, 2010, 10, 86-93.	0.9	15
39	Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive Disease Small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 1039-1045.	0.5	14
40	Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma. Cancer, 2005, 104, 2759-2765.	2.0	13
41	A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer. Cancer Research and Treatment, 2016, 48, 465-472.	1.3	12
42	The Correlation Between Gastric Cancer Screening Method and the Clinicopathologic Features of Gastric Cancer. Medical Oncology, 2003, 20, 265-270.	1.2	6
43	Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies. JTO Clinical and Research Reports, 2021, 2, 100224.	0.6	6
44	A Phase II Study of Dose-Intensified Weekly Concomitant Administration of Cisplatin and Irinotecan in Chemonaive Patients with Extensive-Disease Small-Cell Lung Cancer. Medical Oncology, 2005, 22, 281-290.	1.2	4
45	Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib. Journal of Korean Medical Science, 2013, 28, 1595.	1.1	4
46	ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment, 2017, 49, 678-687.	1.3	3
47	Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2459-2469.	1.2	3
48	Symptom perception and functioning in patients with advanced cancer. PLoS ONE, 2021, 16, e0245987.	1.1	2
49	ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) Journal of Clinical Oncology, 2020, 38, 9601-9601.	0.8	1
50	Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Cancers, 2022, 14, 1512.	1.7	1
51	A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors Journal of Clinical Oncology, 2022, 40, 3105-3105.	0.8	0